Lupin Goa FDA Inspection, October 24, 2026: Form-483 With One Observation

Lupin has one more item on its US regulatory to-do list. In a filing with NSE and BSE on October 24, 2026, the drugmaker said the Lupin Goa FDA inspection ran from October 19 to October 23 and closed with a Form-483 carrying one observation. Lupin says it will address the observation and reply to the US Food and Drug Administration within the stipulated timeframe.

That is the whole of the disclosure. The two-paragraph letter does not say what the observation is about, which products or lines were looked at, or whether this was a routine visit or a pre-approval inspection. So for now, investors are working with a count, not a description.

Lupin Goa FDA inspection: what the filing says

• Site: Lupin’s manufacturing facility in Goa, India.
• Inspection dates: October 19 to October 23, 2026.
• Outcome: Form-483 with one observation.
• Next step: a response to the US FDA within the stipulated timeframe. The company says it is committed to CGMP (current good manufacturing practice) compliance across all its facilities.

The filing was signed by company secretary Amit Kumar Gupta and went to the exchanges on Saturday afternoon, so the next trading session will be the first chance for the stock to react.

Goa was cleared less than a year ago

This is not Goa’s first FDA visit in recent months. On February 27, 2026, Lupin announced it had received the Establishment Inspection Report (EIR) for the same Goa facility with a Voluntary Action Indicated (VAI) classification, which the company called satisfactory. That EIR followed an inspection from November 10 to November 21, 2025. So the plant has now been inspected twice in about eleven months.

How Lupin’s recent 483s have played out

Lupin’s own filings this year give us a useful pattern to watch. Two other sites got 483s in 2026, and both later received EIRs:

• Ankleshwar, Gujarat: inspected March 2 to March 7, 2026, closed with a Form-483 with two observations. Lupin said on May 28 that the site had received its EIR after what it described as a product-specific pre-approval inspection.
• Somerset, New Jersey: inspected April 13 to April 17, 2026, closed with a Form-483 with three observations. On July 1, Lupin said it had received an EIR with VAI classification.

Past outcomes don’t decide this one. Still, a single observation is fewer than either of those two cases, and both ended with an EIR within about three months.

Why the US business makes this worth tracking

The US is Lupin’s biggest market. In its Q1 FY2027 results release of August 6, 2026, the company reported US sales of INR 34,348 million for the June quarter, up 42.9% from INR 24,041 million a year earlier. That was 42% of its global sales. Consolidated sales for the quarter were INR 82,172 million, up 33.3% year on year, and the company said it had 149 generic products in the US market.

With that much revenue tied to US approvals, plant status matters. What we would watch next is Lupin’s response to the observation and, later, the EIR and its classification for Goa. The September-quarter results, when they come, may also carry management’s comments on the site. If you track pharma results, our guide on how to analyse quarterly results shows where regional sales sit in the numbers, and our piece on risk management in trading covers sizing positions around event risk like this.

Disclaimer: This article is for information and education only and is not investment advice. Please do your own research or consult a SEBI-registered adviser before making any investment decision.